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Background: Breast cancer 1-associated protein 1 (BAP1) is a 
nuclear deubiquitinase that regulates gene expression, transcription, 
DNA repair, and more. Several findings underscore the apparent 
driver role of BAP1 in malignant mesothelioma (MM). However, the 
reported frequency of somatic BAP1 mutations in MM varies consid-
erably, a discrepancy that appeared related to either methodological 
or ethnical differences across various studies.
Methods: To address this discrepancy, we carried out comprehen-
sive genomic and immunohistochemical (IHC) analyses to detect 
somatic BAP1 gene alterations in 22 frozen MM biopsies from U.S. 
MM patients.
Results: By combining Sanger sequencing, multiplex ligation-
dependent probe amplification, copy number analysis, and cDNA 
sequencing, we found alteration of BAP1 in 14 of 22 biopsies 
(63.6%). No changes in methylation were observed. IHC revealed 
normal nuclear BAP1 staining in the eight MM containing wild-type 
BAP1, whereas no nuclear staining was detected in the 14 MM biop-
sies containing tumor cells with mutated BAP1. Thus, IHC results 
were in agreement with those obtained by genomic analyses. We then 
extended IHC analysis to an independent cohort of 70 MM biopsies, 
of which there was insufficient material to perform molecular stud-
ies. IHC revealed loss of BAP1 nuclear staining in 47 of these 70 
MM biopsies (67.1%).
Conclusions: Our findings conclusively establish BAP1 as the most 
commonly mutated gene in MM, regardless of ethnic background or 
other clinical characteristics. Our data point to IHC as the most acces-
sible and reliable technique to detect BAP1 status in MM biopsies.
Key Words: Sporadic malignant mesothelioma, Somatic BAP1 
mutation, multiplex ligation-dependent probe amplification, 
Malignant mesothelioma, BAP1.
(J Thorac Oncol. 2015;10: 565–576)
Malignant mesothelioma (MM) is an aggressive tumor that arises from the mesothelial cells that form the lining of 
the pleural, pericardial, and peritoneal cavities.1 In the United 
States, an estimated 3200 people are diagnosed with MM each 
year, with nearly 100,000 new cases expected to occur over 
the next 40 years.2 The association between exposure to asbes-
tos and to other mineral fibers and MM is well established.3 
Only a fraction of asbestos-exposed individuals develop MM, 
indicating that other factors may contribute to the develop-
ment of the disease.1 We have shown that in some families an 
extremely high susceptibility to develop MM is transmitted 
in an autosomal dominant fashion.4 Recently, we identified 
germline mutations in the BRCA-associated protein 1 (BAP1) 
gene as the cause of a novel cancer syndrome characterized 
by a very high incidence of MM and uveal melanoma,5,6 and 
benign atypical melanocytic lesions,7 known as melanocytic 
BAP1-mutated atypical intradermal tumors (MBAITs),8 and 
also by an elevated risk of other malignancies, such as cutane-
ous melanoma,7 renal cell carcinoma,9 cholangiocarcinoma,10 
basal cell carcinoma,11 and possibly more.5,6
BAP1 is a nuclear deubiquitinase, which belongs to 
the ubiquitin C-terminal hydrolase family.12 Among ubiqui-
tin C-terminal hydrolase family members, BAP1 is unique 
because of its long C-terminal tail, which contains two 
nuclear localization signals (NLS1 at 656–661 and NLS2 at 
717–722).13,14 It has been postulated that BAP1 functions as 
a tumor suppressor,6 possibly through three or more mecha-
nisms, all requiring the nuclear localization of the BAP1 
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protein: (1) as component of the Polycomb repressive deu-
biquitinase complex, BAP1 deubiquitinates histone H2A, 
leading to transcriptional activation of genes that regulates 
cell growth15; (2) BAP1 acts as a transcription coregulator, 
associating with host cell factor-1, YY1, and E2F1 to induce 
transcription of genes involved in cell cycle regulation12,16–18; 
and (3) BAP1 contributes to the process of DNA repair.6,19,20 
Whether BAP1 also has some presently unknown cytoplasmic 
activity remains unknown.
Somatic BAP1 mutations are found in sporadic MM 
(i.e., MMs that occur in individuals that do not carry germline 
BAP1 mutations), as well as in other malignancies, although 
the frequency of BAP1 mutations varies widely across differ-
ent tumor types. Pena-Llopis et al.21 detected somatic BAP1 
mutations in 14% of renal cell carcinoma specimens (24 of 
176 tumors) using Sanger and whole-genome sequencing, 
whereas Harbour et al.22 detected mutations in 84% of metas-
tasizing uveal melanoma biopsies (26 of 31) using next-gen-
eration sequencing (NGS). In sporadic MM, by using Sanger 
sequencing, we found somatic BAP1 mutations in 22% of U.S. 
Caucasian MM biopsies (4 of 18).5 These results are in accor-
dance with the results of Bott et al.23 and Zauderer et al.,24 who 
found 23% (12 of 53) and 20% (24 of 121) BAP1 mutations in 
sporadic U.S. MM, also by Sanger sequencing. We described 
loss of BAP1 nuclear staining in MM tumor biopsies contain-
ing mutated BAP1.5 We and Bott et al.23 also noted loss of 
BAP1 nuclear staining in some MM biopsies that apparently 
had wild-type BAP1 according to Sanger sequencing. Arzt 
el al.25 revealed absence of BAP1 nuclear staining in 60% of 
123 MM biopsies in a study that was based exclusively on 
immunohistochemistry (IHC). Yoshikawa et al.26 found that 
BAP1 was mutated in 61% of cell cultures (14 of 23) derived 
from pleural fluids of Japanese MM patients. In this study, 
Yoshikawa et al.26 performed microarray-based comparative 
genomic hybridization (array CGH), Sanger sequencing, and 
real-time polymerase chain reaction (PCR) on DNA extracted 
from tumor cells established in tissue culture, after several sub-
cultures. Instead, our study5 and the studies by Bott et al.23 and 
Zauderer et al.24 were based on Sanger sequencing of tumor 
DNA from primary frozen tissue biopsies. The significant dif-
ference in frequency of BAP1 mutations reported may due to 
differences in ethnicities of the patients studied, lack of sensi-
tivity and/or reproducibility of Sanger sequencing or IHC in 
detecting BAP1 mutations, procedure of tumor cell isolation 
and accumulation of novel BAP1 mutations by MM cells in 
tissue culture,26 lack of specificity of IHC, or some other dif-
ferences in methodology. To investigate the basis of the dis-
crepancies between these studies and to try to conclusively 
address this issue, we performed multiplex molecular analyses 
to comprehensively identify all possible genetic alterations of 
the BAP1 gene in sporadic MM biopsies. We found that BAP1 
is mutated in more than 60% of MM specimens.
MATERIALS AND METHODS
Specimen Collection
Twenty-two MM frozen biopsies and matching normal 
leukocytes were obtained from the New York University (NYU) 
Langone Medical Center (HIP). MM samples were harvested 
during surgery and immediately frozen in liquid nitrogen.
An independent cohort of 70 formalin-fixed paraf-
fin-embedded tissue slides was obtained from the National 
Mesothelioma Virtual Bank (NMVB) at the University of 
Pittsburgh. These latter specimens were used exclusively to 
extend BAP1 IHC analyses, as the amount of tissue available 
was insufficient to perform molecular studies. Specimens 
were de-identified before analysis. Sex, ethnicity, asbestos 
exposure, age at diagnosis, histology, and stage data were 
collected and are reported in the Supplementary Table 1A 
(Supplemental Digital Content 1, http://links.lww.com/JTO/
A775).
Germline BAP1 wild-type (WT) DNAs were obtained 
from healthy volunteers. Written and informed consent was 
obtained from all patients included in these studies according 
to the guidelines set forth by the institutional review boards.
Laser Capture Microdissection
Laser capture microdissection was performed to 
enrich tumor cells from frozen tissue specimens for DNA 
and RNA isolation. The detailed procedure is described in 
Supplementary material (Supplemental Digital Content 2, 
http://links.lww.com/JTO/A776).
DNA and RNA Extraction
DNA was extracted using DNeasy Blood & Tissue 
Kit (Qiagen, Hilden, Germany) or QiAamp DNA Micro Kit 
(Qiagen 56304) as per manufacturer’s instructions. Total RNA 
was extracted using mirVana miRNA isolation kit (Ambion, 
Austin, TX) as per manufacturer’s instructions. Sample qual-
ity was evaluated by nanodrop. The 260/280 ratio was between 
1.66 and 2.07 for DNA samples and between 1.94 and 2.15 for 
RNA samples.
Real-Time PCR
Total RNA was converted to cDNA using ImProm-II 
Reverse Transcription System (Promega, Madison, WI), fol-
lowing the manufacturer’s instructions. A double-strand cDNA 
library was synthesized using the LD PCR kit (SMART cDNA 
Library Construction Kit; Clontech Laboratory, Mountain 
View, CA) according to the manufacturer’s instructions.
DNA and RNA Sequencing Analysis
Conventional Sanger sequencing was performed 
as described.5 Genomic BAP1 PCR product sizes ranged 
from 560 to 670 base pairs (bp) with 100 to 150 bp overlap 
between primer sets. A similar primer design was employed 
for cDNA sequencing. Sequencing was conducted using 
the ABI 3730XL DNA Sequencer, at the Advanced Studies 
in Genomics, Proteomics and Bioinformatics facility at the 
University of Hawai’i at Manoa.
Multiplex Ligation-Dependent 
Probe Amplification Assay
Multiplex ligation-dependent probe amplification 
(MLPA) is a reliable technique extensively validated for 
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detection of medium and large gene alterations, which can-
not be detected by conventional Sanger sequencing.27,28 
MLPA assay was performed according to the manufacturer’s 
protocol (SALSA MLPA probemix P417-B1 BAP1; MRC-
Holland, Amsterdam, The Netherlands). The detailed proce-
dure is described in Supplementary material (Supplemental 
Digital Content 2, http://links.lww.com/JTO/A776) and 
Supplementary Figure 3 (Supplemental Digital Content 3, 
http://links.lww.com/JTO/A777).
Immunohistochemistry
IHC analysis of BAP1 protein expression was per-
formed as described using a mouse monoclonal anti-BAP1 
antibody (C-4: Santa Cruz Biotechnology, Dallas, TX).5 
This antibody recognizes the epitope between aa 430 and 
739; therefore, it is predicted to detect BAP1 wild-type 
and mutant forms that retain the NLS. We had previously 
reported that BAP1 is expressed in normal pleural cells.8 
We extensively validated this antibody for the detection of 
nuclear BAP1 on a number of normal human pleural sam-
ples—all showing nuclear staining in 100% of pleural cells, 
as well as on MM-derived cell lines in which BAP1 gene 
status has been comprehensively characterized in our labo-
ratory. Histologically normal pleura and liver biopsies from 
autopsies were used as positive and negative controls, respec-
tively, for BAP1 nuclear staining. Liver biopsies were chosen 
because they were shown to contain negligible amounts of 
BAP1 (http://www.proteinatlas.org/ENSG00000163930-
BAP1/tissue/liver). We confirmed that BAP1 does not stain 
the nuclei of liver cells.
Two U.S. board-certified pathologists with extensive expe-
rience in MM diagnosis (MC and AP) independently reviewed 
all IHC results and concurred with their interpretation. The 
patients’ characteristics of the control materials are not known, 
and this information cannot be obtained due to Health Insurance 
Portability and Accountability Act (HIPAA) constraints.
Promoter Methylation Analysis
Tumor DNA was modified with sodium bisulfide by 
using EZ DNA methylation kit (ZYMO research, Orange, CA) 
according to the manufacturer’s protocol. The detailed proce-
dure is described in Supplementary material (Supplemental 
Digital Content 2, http://links.lww.com/JTO/A776).
Whole Gene Methylation Analysis
BAP1 gene body methylation analysis was per-
formed using the Methyl Primer Express Software v1.0 
(Applied Biosystems, Grand island, NY), as described in 
Supplementary material (Supplemental Digital Content 2, 
http://links.lww.com/JTO/A776).
TaqMan Copy Number Assay
TaqMan copy number assay was performed at the 
Genomics Shared Resource, University of Hawai’i Cancer Center, 
according to the manufacturer’s instructions (Supplementary 
material, Supplemental Digital Content 2, http://links.lww.
com/JTO/A776).
Statistical Analysis
We studied the relationship between BAP1 mutation 
status and age, sex, ethnicity, asbestos exposure, and histol-
ogy using Fisher’s exact test. Epithelioid MMs were compared 
with all other histological types; MM from patients older than 
65 years were compared with all the others; patients exposed 
to asbestos were compared with all the others. Overall survival 
was estimated using the Kaplan-Meier method. Patients alive 
at the end of the study were censored at the time of the last 
available follow-up. Using the log-rank test, we compared sur-
vival between MM patients with altered BAP1 versus patients 
with wild-type BAP1.
RESULTS
Sanger Sequencing and IHC for BAP1
Sanger sequencing was performed on DNA extracted 
from laser microdissected tumor cells and from match-
ing germline DNA isolated from blood leukocytes of each 
of 22 MM patients. Matching germline DNA was found 
to contain the wild-type BAP1 gene in 22 of 22 samples. 
Sequencing analysis detected BAP1 alterations in a total 
of 6 of the 22 MM biopsies tested (27.3%, Table 1), which 
is in accordance with our previous findings.5 The 22 MM 
biopsies included 15 samples that had been tested previ-
ously by Sanger sequencing, whose DNA was re-extracted 
from a separate vial containing frozen tumor tissue, and 
seven samples not previously analyzed yet. All 22 samples 
were analyzed blindly to test for reproducibility. The results 
obtained using Sanger sequencing were very reproducible 
as the same four samples that had tested positive for BAP1 
mutations, NYU647, NYU658, NYU866, and NYU937 
previously,5 retested positive and the 11 samples that had 
tested negative5 retested negative (Table 1). These find-
ings indicated that Sanger sequencing of DNA from tumor 
cells laser microdissected from frozen MM biopsies is very 
sensitive and specific in detecting at least certain types of 
BAP1 DNA alterations.
In addition, we identified two new BAP1 mutations 
among the seven new MM biopsies, while five tested nega-
tive (BAP1 wild type). A point mutation (G → T) was found 
at the end of intron 14 on the genomic DNA of NYU524 (Fig. 
1A). cDNA sequencing of this region revealed a 70 nucleo-
tide insertion of an extra sequence from intron 14 (Fig. 1B). A 
single G insertion in exon 14 was detected in MM NYU1024 
by sequencing both genomic DNA and cDNA (Fig. 1C). This 
variant encodes a presumed truncated BAP1 protein (642aa) 
missing the NLS as a result of the frameshift mutation (Fig. 
1D). Overall, Sanger sequencing detected BAP1 mutations in 
6 of 22 samples (27.3%) all predicted to result in truncated 
proteins lacking the NLS.
IHC showed complete lack of BAP1 nuclear staining in 
100% of tumor cells of these six mutated samples. Unexpectedly, 
in eight additional biopsies that appeared to contain wild-type 
BAP1 by Sanger sequencing, no nuclear staining was detected. 
Overall, 14 of 22 MM biopsies (63.6%) contained tumor cells 
lacking BAP1 nuclear staining. Instead, the nuclei of the tumor 
cells of the additional eight MM biopsies carrying wild-type 
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BAP1, as detected by Sanger sequencing, uniformly (all tumor 
cells) stained for BAP1 (Fig. 2).
MLPA, TaqMan Copy Number Analysis, 
and cDNA Sequencing Detected a 
Number of Previously Unidentified Gross 
Alterations of BAP1 in Somatic MM
Tumor DNA from NYU540, NYU559, NYU1419, 
NYU207, NYU851, NYU966, NYU1306, and NYU1250 
appeared to contain wild-type BAP1 according to Sanger 
sequencing, while none of the tumor cells displayed nuclear 
BAP1 staining (Fig. 2). NYU540 tumor DNA displayed 
homozygous deletion of the entire BAP1 gene by MLPA 
analysis (average normalized dosage quotient [NDQ] of 
all exon = 0.387; Fig. 3A). This deletion was confirmed by 
TaqMan copy number analysis (Fig. 3B). NYU559 tumor 
DNA showed a homozygous deletion from exon 4 to exon 
17 by MLPA analysis (exons 4–17 average NDQ = 0.267; 
Fig. 3C, D). MLPA also revealed a homozygous deletion of 
the BAP1 gene in NYU1419, with the lowest NDQ value of 
0.27 for exon 12 (Fig. 3E). These results were confirmed 
by TaqMan copy number assay (Fig. 3F). A 3919-bp dele-
tion spanning exon 7 to 13 was detected in NYU207 tumor 
DNA by MLPA analysis and TaqMan copy number assay 
(NDQ value of 0.407 at exon 12; Fig. 3G, H), which was fur-
ther confirmed by genomic DNA sequencing using primers 
specifically designed to detect this deletion (Supplementary 
Figure, Supplemental Digital Content 4, http://links.lww.
com/JTO/A778). cDNA sequencing (c.437_1729del 1293) 
revealed that this deletion would result in a putative truncated 
protein (210 aa) lacking the NLS.
Three additional MM biopsies (NYU851, NYU966, and 
NYU1306) appeared to contain wild-type BAP1 by Sanger 
sequencing, yet they lacked nuclear BAP1 staining (Fig. 2). 
These three tumors displayed various types of copy number 
alterations in BAP1 exons by MLPA. As shown in Figure 4, 
NYU851 tumor DNA showed low NDQ values in exons 1, 4, 
and 15 (Fig. 4A). Aberrant splicing was found between exon 
8 and exon 9 and cDNA sequencing identified the deletion of 
1820 nucleotides from 1003 to 2822 (c.1003_2822 del 1820; 
Fig. 4B). NYU966 showed decreased copy number of exon 
1 and exon 4 (Fig. 4C), while cDNA sequencing identified a 
transcript with deletion of 769 nucleotides from 1128 to 1896 
(c.1128_1896del 769; Fig. 4D). An increase in exon copy 
number was detected in multiple BAP1 exons using MLPA in 
tumor NYU1306, particularly exons 1 to 3, 7 to 9, and 10 to 17 
showing a NDQ value above 1.4 (Fig. 4E). This copy number 
increase was confirmed by TaqMan Assay (Supplementary 
Figure, Supplemental Digital Content 5, http://links.lww.
com/JTO/A779). Moreover, NYU1306 cDNA sequencing 
identified a deletion of 791 nucleotides from 1101 to 1891 
leading to a putative truncated BAP1 (c.1101_1891 del 791, 
400aa; Fig. 4F).
FIGURE 1.  Point mutations of 
BAP1 genes detected by Sanger 
sequencing. A, Tumor NYU524. 
Genomic DNA sequencing shows 
point mutation (G → T) at the 
splicing site at the end of intron 
14. B, cDNA sequencing revealed 
a 70 nucleotide insertion from part 
of intron 14 (c.1891_1892Ins 70, 
p.Glu630fsX23). C, Tumor NYU1024. 
Genomic sequencing displayed G 
insertion in exon 14 (c.1762_1763 
Ins G). D, cDNA sequence of the cor-
responding region (p.Pro588fsx55).
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NYU1250 also lacked nuclear BAP1 staining (Fig. 2). 
However, in this sample, neither Sanger sequencing nor 
MLPA could identify BAP1 alterations. cDNA sequencing 
detected a splicing mutant (c.1250_1371 del 122) in which 
the end of exon 12 was juxtaposed to the middle of exon 13 
(Fig. 4G). A cryptic splicing site AG was found at the junc-
tion, which may generate a putative BAP1 protein of only 531 
amino acids lacking the NLS (p.Tyr418fsx113; Fig. 4H). This 
splicing variant has not been reported previously (National 
Center for Biotechnology Information and GeneCards from 
the Weizmann Institute of Science).
Three samples showed BAP1 alterations using both, 
Sanger sequencing and MLPA. NYU937 showed a reduced 
NDQ of exon 9. Sanger sequencing revealed a point mutation 
in the region of the MLPA probe for exon 9 (Supplementary 
Figure, Supplemental Digital Content 3, http://links.lww.
com/JTO/A777). MLPA also detected allele deletions in 
NYU tumor biopsies 866 and 1024 (Supplementary Figure, 
Supplemental Digital Content 6, http://links.lww.com/JTO/
A780), which were shown by Sanger sequencing to contain 
DNA mutations in the other allele and lacked BAP1 nuclear 
staining (Figs. 1C, 2). Together these analyses revealed loss of 
heterozygosity (LOH) for these two samples.
No deletions were detected by MLPA, or by other 
techniques, in MM samples NYU047, NYU0217, NYU269, 
NYU517, NYU809, NYU929, NYU1017, and NYU1359. 
IHC revealed positive BAP1 nuclear staining in 100% of the 
tumor cells in these eight biopsies (Fig. 2 and Table 1).
BAP1 Promoter and Body Methylation 
Are Not Altered in MM
We sought to determine whether DNA methylation 
could be an additional mechanism leading to BAP1 inac-
tivation in sporadic MM. Transcriptional silencing may 
occur through methylation around the transcriptional start 
site; therefore, seven CpG loci, located approximately 
450-bp upstream of ATG start codon, were used to check 
the methylation status of BAP1 (Supplementary Figure, 
Supplemental Digital Content 7, http://links.lww.com/JTO/
A781). Bisulfite-converted pyrosequencing revealed 86% 
to 98% methylation in a human high methylation genomic 
DNA control (Supplementary Figure, Supplemental Digital 
Content 7, http://links.lww.com/JTO/A781), whereas 2% to 
4% methylation was detected in the low methylation con-
trol (Supplementary Figure, Supplemental Digital Content 
7, http://links.lww.com/JTO/A781). We analyzed all 22 spo-
radic MM biopsies and found a consistently low level (1–4%) 
of methylation in all the samples. Methylation analysis of 
patient samples NYU047 and N524 is shown as an example 
(Fig. 5 and Table 1). These results indicate that hypermethyl-
ation is not a significant mechanism for BAP1 inactivation in 
MM. Recently, gene body methylation was found positively 
correlated with gene expression.29 Therefore, we investi-
gated whether BAP1 body methylation may influence BAP1 
gene expression. Using The Cancer Genome Atlas (TCGA) 
database, we analyzed BAP1 methylation in several tumor 
types, at 19 sites spanning the entire BAP1 promoter, gene, 
and 3′ untranslated region (Fig. 5C). Four probes located in 
the body region and 3′ untranslated region were uniformly 
heavily methylated in all nonmalignant and malignant tis-
sues examined. The remaining 15 probes including all the 
ones located in the promoter/exon 1 region were completely 
or nearly completely unmethylated in all tissue samples 
examined (Fig. 5C and Supplementary Tables, Supplemental 
Digital Content 8, http://links.lww.com/JTO/A782, and 
Supplemental Digital Content 9, http://links.lww.com/JTO/
A783), support the interpretation that methylation plays no 
role in the inactivation of the BAP1 gene.
Extended IHC Analyses on a 
Separate MM Cohort
Our genetic results were very consistent with BAP1 
IHC results, as all BAP1 gene alterations detected resulted 
in loss of BAP1 nuclear staining by IHC. Thus, IHC appeared 
FIGURE 2.  Detection of BAP1 protein expression in sporadic 
malignant mesothelioma tumor samples by immunohisto-
chemistry. Wild-type BAP1 tumor sample NYU047 shows 
strong nuclear staining in all tumor cells. All samples carry-
ing alteration of BAP1 gene are shown (photomicrographs 
magnification, 400×).
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a reliable method to identify MM biopsies containing 
mutated BAP1.
To extend these results, we performed BAP1 IHC on 
unstained paraffin embedded glass slides from an indepen-
dent, annotated cohort from the NMVB (Supplementary 
Table, Supplemental Digital Content 1, http://links.lww.
com/JTO/A775) consisting of a total of 70 cases of U.S. 
MM biopsies, of which we did not have additional mate-
rial to conduct genetic analyses. This cohort included 63 
Caucasian and seven non-Caucasian cases. We found loss 
of BAP1 nuclear staining in 47 of all 70 MM (67.1%) 
and in 44 of the 63 Caucasian MM biopsies (69.8%) 
(Supplementary Table, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A775).
Patients’ Demographics and 
Possible Clinical Correlations
Overall, the MM patients studied appeared to have 
received similar treatments as 45% of BAP1-altered and 
44% of patients with normal BAP1 had surgery, and 35% 
of BAP1-altered and 31% of patients with normal BAP1 
received chemotherapy (Supplementary Table, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A775); thus, it is 
unlikely that treatment influenced some of the results. We did 
not find significant relationships between frequency of BAP1 
alterations and sex, age of diagnosis, ethnicity, or history 
of asbestos exposure (Supplementary Table, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A775). Patients 
FIGURE 3.  Gross BAP1 gene alterations detected by 
MLPA and TaqMan copy number assays. MLPA assay is 
measured at 17 points, one each on 17 exons of BAP1 
gene. TaqMan copy number assay is measured at six 
points on BAP1 gene; one each on exons 2, 3, 6,  
12, 14, and 17. NYU540 MLPA and TaqMan data  
(A, B), NYU559 MLPA and TaqMan data (C, D), 
NYU1419 MLPA and TaqMan data (E, F), and NYU207 
MLPA and TaqMan data (G, H). MLPA = multiplex 
ligation-dependent probe amplification.
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FIGURE 4.  Detection of aberrant forms of BAP1 by MLPA and cDNA sequencing. A, Tumor NYU851. MLPA assay detected deletions 
of exons 1, 4, and 15. B, NYU851 cDNA sequencing revealed two aberrant splicing at exons 8–9 and exons 11–17 in one allele.  
C, MLPA on NYU966 showed deletion of exons 1 and 4. D, Tumor NYU966 cDNA sequencing revealed a cDNA with skipping 
of most of exons 12, 13, 14, and 6 bp of exon 15 as well as a wild-type cDNA (exons 14 and 15 shown). E, MLPA on NYU1306 
detected triplication, copy number increase to three copies, in most exons. F, NYU1306 cDNA sequencing revealed a deletion 
of exons 12 and 13. G, NYU1250 cDNA sequencing revealed a new splicing isoform of BAP1 due to a 121-bp deletion in exon 
13. H, Aberrant usage of cryptic splicing site AG, found in NYU1250, is shown by arrow on reference DNA sequence at intron 
12 and exon 13. Nucleotides in green indicate the exon sequence. MLPA = multiplex ligation-dependent probe amplification.
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with altered BAP1 had similar survivals than those with nor-
mal BAP1 (Supplementary Figure, Supplemental Digital 
Content 10, http://links.lww.com/JTO/A784). This was 
expected as each cancer contains many genetic alterations 
and it would be highly unlikely that mutations of a single 
gene influence prognosis. There was an apparent increased 
frequency of BAP1 alterations in patients with epithelial type 
MM versus other histological subtypes. However, the possi-
ble significance of all of these clinical correlates is tempered 
by the small sample size.
DISCUSSION
Using an integrated molecular approach that included 
Sanger sequencing, MLPA, TaqMan copy number analy-
sis, messenger RNA sequencing, and IHC (Supplementary 
Figure, Supplemental Digital Content 11, http://links.lww.
com/JTO/A785), we conclusively demonstrate that the major-
ity (14 of 22, 63.6%) of sporadic MMs contain somatic BAP1 
mutations. Our study underscores the need of using distinct 
technical approaches to identify the nature of the differ-
ent types of BAP1 mutations possibly causing lack of BAP1 
nuclear staining.
Our results indicate that the use of a single molecular 
technique is insufficient to detect all types of BAP1 alterations. 
Although Sanger sequencing is reliable to detect single point 
mutations, which are various and frequent in MM and other 
cancer types,5,8,21,26,30,31 the MLPA assay is much more reliable 
to detect large deletions.32 We found that Sanger sequencing 
was very reliable and reproducible in detecting BAP1 point 
mutations and small deletions in preparations of DNA from 
laser dissected MM biopsies containing over 80% purity of 
tumor cells. However, this technique could not detect large 
DNA deletions. Conversely, MLPA was reliable to detect large 
exon gains and losses, even under conditions of relatively low 
sample purity (~50% of tumor cells). In this setting, MLPA is 
cost-efficient compared with array CGH, fluorescence in situ 
hybridization, and gene copy number assay.33 However, MLPA 
could not detect single-nucleotide changes unless they fall 
within the MLPA probe target regions. In our study, 6 of 14 
mutations were detected using conventional Sanger sequenc-
ing. Of these six mutations, five were not detected by MLPA 
because the mutated regions were small and not covered by 
the MLPA probe. On the other hand, seven additional aber-
rant forms of the BAP1 gene were identified by the MLPA 
assay. Since the regions of exon copy number changes in these 
seven biopsies are large, Sanger sequencing could not detect 
these mutations. For accurate detection of deletions of large 
exons, such as exon 13 of BAP1, several MLPA probes had 
to be used. Abnormal splicing forms were detected in one 
MM biopsy—in which both Sanger sequencing and MLPA 
had not found any alteration—by RNA sequencing. Introns 
contain splicing enhancers and silencers,34–36 which may par-
tially explain the presence of some aberrant splicing variants 
in these MM samples.
FIGURE 5. BAP1 promoter and body methylation analysis. A, Sample NYU047. B, Sample NYU524. Low BAP1 promoter meth-
ylation was detected by pyrosequencing in all sporadic MM samples tested. Pyrosequencing values detected in MM tumor sam-
ples are as low as the normal control DNA. Two representative samples are shown, where yellow highlights indicate the percentage 
of methylation at each site. C, The Cancer Genome Atlas portal database (https://tcga-data.nci.nih.gov/tcga/) was examined 
for methylation at BAP1 gene, which was covered by 19 probes (data generated by use of the Infinium HumanMethylation450 
BeadChip). MM = malignant mesothelioma.
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Six of 14 MM biopsies had homozygous BAP1 dele-
tions as determined by both genomic analyses and IHC. For 
the remaining eight additional mutated samples, lack of 
nuclear staining supports LOH. However, molecular stud-
ies could not definitely establish LOH, possibly because 
traces of contaminant normal cell DNA were present in the 
samples.
There was 100% concurrence between detection of 
some molecular alterations in 14 of 22 biopsies and absence 
of BAP1 nuclear staining (Table 1 and Fig. 2). Strong nuclear 
and weaker cytoplasmic BAP1 IHC reliably identified the 
eight MM biopsies containing wild-type BAP1 from 14 
biopsies containing mutated BAP1, whose nuclei did not 
stain for BAP1. Among the 14 mutated biopsies, seven con-
tained tumor cells lacking BAP1 staining entirely (Fig. 2). 
Cytoplasmic BAP1 tumor cell staining was detected in seven 
biopsies with genetically mutated BAP1 (Fig. 2). Cytoplasmic 
staining can be expected when mutations result in a truncated 
BAP1 protein lacking the NLS or bearing mutations in the 
catalytic subunit that prevent BAP1 auto-deubiquitination 
which is required for nuclear localization.37 All mutated forms 
of BAP1 detected here and in previous publications fall in this 
category and, therefore, are expected to lead to similar bio-
logical effects, as they all cause complete BAP1 protein loss 
or BAP1 isoforms sequestered in the cytoplasm and thus loss 
of BAP1 nuclear activity.
These results suggest that IHC may be the most reli-
able and accessible method to identify MM biopsies that 
harbor BAP1 genetic alterations, while much more expen-
sive and time-consuming genetic approaches can be used 
to (1) confirm the IHC findings, (2) detect heterozygosity, 
and (3) understand the mechanisms leading to loss of BAP1 
expression.
To this date, all BAP1 activities have been related to 
nuclear localization.10,13,14 Analysis of a separate cohort of MM 
biopsies from the NMVB revealed lack of BAP1 nuclear stain-
ing in 47 of 70 biopsies (67.1%), confirming the high frequency 
of BAP1 mutations in U.S. MMs. Of note, in this cohort, six 
specimens contained a mixed tumor cell population, some with 
and some without BAP1 nuclear staining, possibly a result 
related to intratumoral heterogeneity and/or polyclonality.38,39
Promoter methylation is a common mechanism of 
tumor suppressor gene inactivation in several MM and other 
tumor types.40,41 For example, Ras association (RalGDS/
AF-6) domain family member 1 (RASSF1) and E-cadherin 
promoter hypermethylation was detected in MM patients.42,43 
High expression of DNA methyltransferases (DNMT1) was 
detected in pleural MM.44 However, we observed no differ-
ences in methylation of the BAP1 promoter or gene body. 
Similarly, no BAP1 methylation alterations were found in 
clear cell renal carcinoma.45 Whole-body methylation was 
also examined, considering the increasing volume of publica-
tions documenting a role of body methylation in gene expres-
sion.29 While methylation data on MM are not available yet 
within the TCGA database, the data collected from multiple 
other tumor types indicate that methylation plays no role in the 
inactivation of the BAP1 gene. In summary, DNA methylation 
does not seem to be a mechanism that contributes to BAP1 
inactivation in sporadic MM.
Although the information of demographics, histology, 
and survival is presented, we are not elaborating about pos-
sible clinical correlation with BAP1 status as the relatively 
small size of this cohort may bias interpretation.
In summary, our results demonstrate that: (1) BAP1 
inactivation in MM is achieved primarily by DNA mutation 
and changes in exon copy number; (2) different types of muta-
tions lead to BAP1 lacking nuclear localization as shown by 
absence of BAP1 nuclear staining in all of the mutated samples 
and; (3) ethnicity does not seem to influence the frequency of 
BAP1 alterations.
Previously cyclin-dependent kinase inhibitor 2A/2B 
(CDKN2A/2B) and neuriofibromin 2 (NF2) have been consid-
ered the most commonly mutated tumor suppressor genes in 
MM as they are found mutated in 30% to 50% and 35% to 
40% of human MM biopsies, respectively.46,47 However, the 
high percentage of BAP1 mutations that we found in sporadic 
MM (>60%) now identifies BAP1 as the most commonly 
mutated gene in this malignancy.
Our findings are supported by two recent NGS studies of 
the MM genome by Guo et al.48 and Lo Iacono et al.49 These two 
NGS studies revealed that various inactivating mutations occur 
randomly and are rarely shared among MM biopsies, with the 
exception of BAP1 that was found mutated in 41%48 and 58%49 
of MMs, respectively, and to a lesser extent NF2, CDKN2A48,49, 
and possibly CUL1.48 Lo Iacono et al.49 also performed IHC 
studies and found that 52% of 116 MM biopsies from 116 
patients stained for nuclear BAP1, an indication of normal 
BAP1 activity, whereas 48% did not, an indication of mutated 
BAP1.49 BAP1 staining correlated with presence/absence of 
DNA mutations (p = 0.001)—of note in the same study NF2 
staining did not—independently supporting our findings that 
IHC is a reliable technology to identify BAP1 mutations.49
Guo et al.48 performed whole-exome sequencing of 22 
MM biopsies from 22 MM patients and found 490 mutated 
genes of which 447 were mutated only in one biopsy. BAP1 
alterations were the most frequent mutations as they were 
detected in 41% of the 22 biopsies they studied, followed 
by CDKN2A and NF2. Six of these 22 MM biopsies were 
also included in our study (NYU269, NYU517, NYU647, 
NYU658, NYU929, and NYU937), allowing a direct com-
parison of the sensitivity of the technology used to detect 
BAP1 mutations. In accordance with our results, Guo et 
al.48 found that samples NYU269, NYU517, and NYU929 
contained wild-type BAP1. They also detected the identi-
cal BAP1 mutation in sample NYU937 (p.Ile499fsX15). 
However, although we detected homozygous mutations in 
samples NYU647 and NYU658 by Sanger sequencing—
further confirmed by lack of nuclear staining by IHC—Guo 
et al.48 did not (Table 1). This discrepancy may be due to the 
limitations of the NGS approach, which can produce base 
substitution errors, and to the fact that differently from Guo 
et al.,48 we laser microdissected tumor cells from the biopsy, 
thus decreasing/eliminating the background of contaminat-
ing normal cells that contain wild-type BAP1. Alternatively, 
this discrepancy may be due to intratumor heterogeneity38 
and/or polyclonality.39
Our results and those from these two recent NGS MM 
studies underscore the apparent driver role of BAP1 in MMs 
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and point at BAP1 as a potentially useful therapeutic target. 
In addition, somatic mutations in BAP1 are present in other 
malignancies6; thus, therapies to restore BAP1 activity are of 
potential relevance to many cancer patients.
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